MX367796B - Usos médicos para tratar hepatitis c. - Google Patents

Usos médicos para tratar hepatitis c.

Info

Publication number
MX367796B
MX367796B MX2015003501A MX2015003501A MX367796B MX 367796 B MX367796 B MX 367796B MX 2015003501 A MX2015003501 A MX 2015003501A MX 2015003501 A MX2015003501 A MX 2015003501A MX 367796 B MX367796 B MX 367796B
Authority
MX
Mexico
Prior art keywords
methods
treating hepatitis
inhibitors
hepatitis
hcv
Prior art date
Application number
MX2015003501A
Other languages
English (en)
Other versions
MX2015003501A (es
Inventor
M Kati Warren
A Matulenko Mark
G Keddy Ryan
K Pratt John
J Maring Clarence
Wagner Rolf
Liu Dachun
Krishnan Preethi
Teresa, (Lok-Chan) Ng
J Pilot-Matias Tami
C Mistry Neeta
J Reisch Thomas
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367796(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015003501A publication Critical patent/MX2015003501A/es
Publication of MX367796B publication Critical patent/MX367796B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a inhibidores de VHC pan-genotípicos. Esta invención también se relaciona a métodos para utilizar estos inhibidores para utilizar estos inhibidores para tratar infección por VHC.
MX2015003501A 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c. MX367796B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18
PCT/US2013/060103 WO2014047039A1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c

Publications (2)

Publication Number Publication Date
MX2015003501A MX2015003501A (es) 2015-10-26
MX367796B true MX367796B (es) 2019-09-06

Family

ID=49304326

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003501A MX367796B (es) 2012-09-18 2013-09-17 Usos médicos para tratar hepatitis c.
MX2019010600A MX2019010600A (es) 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010600A MX2019010600A (es) 2012-09-18 2015-03-18 Usos médicos para tratar hepatitis c.

Country Status (25)

Country Link
US (1) US20140080868A1 (es)
EP (2) EP3597190A1 (es)
JP (4) JP6297044B2 (es)
CN (1) CN104797253A (es)
AU (2) AU2013318302B2 (es)
BR (1) BR112015006037B1 (es)
CA (1) CA2884539C (es)
CY (1) CY1122442T1 (es)
DK (1) DK2897611T3 (es)
ES (1) ES2755089T3 (es)
HR (1) HRP20191939T1 (es)
HU (1) HUE046544T2 (es)
LT (1) LT2897611T (es)
MX (2) MX367796B (es)
NZ (1) NZ630581A (es)
PL (1) PL2897611T3 (es)
PT (1) PT2897611T (es)
RS (1) RS59640B1 (es)
RU (1) RU2665365C2 (es)
SG (2) SG10201702248UA (es)
SI (1) SI2897611T1 (es)
SM (1) SMT201900683T1 (es)
TW (1) TWI621436B (es)
WO (1) WO2014047039A1 (es)
ZA (1) ZA201501752B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2897611T3 (pl) * 2012-09-18 2020-03-31 Abbvie Inc. Sposób leczenia wirusowego zapalenia wątroby typu C
WO2015153792A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
KR20210013344A (ko) * 2013-03-14 2021-02-03 애브비 인코포레이티드 C형 간염 치료용 2가지 항바이러스제의 병용물
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US10286029B2 (en) 2013-03-14 2019-05-14 Abbvie Inc. Method for treating HCV
RU2018102809A (ru) * 2015-06-26 2019-07-29 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
JP6808660B2 (ja) * 2015-07-08 2021-01-06 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
CR20180088A (es) * 2015-07-17 2018-05-24 Abbvie Inc Composiciones farmacéuticas sólidas para el tratamiento del vhc
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008010355A (es) * 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DE202012012955U1 (de) * 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
PL2897611T3 (pl) * 2012-09-18 2020-03-31 Abbvie Inc. Sposób leczenia wirusowego zapalenia wątroby typu C

Also Published As

Publication number Publication date
JP6297044B2 (ja) 2018-03-20
SI2897611T1 (sl) 2019-12-31
TWI621436B (zh) 2018-04-21
RU2015114543A (ru) 2016-11-10
ES2755089T3 (es) 2020-04-21
HRP20191939T1 (hr) 2020-01-10
DK2897611T3 (da) 2019-11-04
BR112015006037B1 (pt) 2022-05-17
JP2021054849A (ja) 2021-04-08
RU2665365C2 (ru) 2018-08-29
TW201412311A (zh) 2014-04-01
AU2018203608B2 (en) 2019-12-19
US20140080868A1 (en) 2014-03-20
BR112015006037A2 (pt) 2017-07-04
AU2018203608A1 (en) 2018-06-14
HK1209319A1 (en) 2016-04-01
EP2897611B1 (en) 2019-07-24
EP3597190A1 (en) 2020-01-22
PT2897611T (pt) 2019-11-27
AU2013318302B2 (en) 2018-02-22
AU2013318302A1 (en) 2015-04-02
CA2884539C (en) 2022-06-21
JP2019194241A (ja) 2019-11-07
EP2897611A1 (en) 2015-07-29
CA2884539A1 (en) 2014-03-27
JP2015528511A (ja) 2015-09-28
WO2014047039A1 (en) 2014-03-27
MX2019010600A (es) 2020-02-03
CY1122442T1 (el) 2021-01-27
JP6556884B2 (ja) 2019-08-07
MX2015003501A (es) 2015-10-26
PL2897611T3 (pl) 2020-03-31
CN104797253A (zh) 2015-07-22
JP2018109035A (ja) 2018-07-12
HUE046544T2 (hu) 2020-03-30
NZ630581A (en) 2017-02-24
LT2897611T (lt) 2019-12-10
SG11201502095SA (en) 2015-05-28
ZA201501752B (en) 2016-08-31
RS59640B1 (sr) 2020-01-31
SG10201702248UA (en) 2017-04-27
SMT201900683T1 (it) 2020-01-14

Similar Documents

Publication Publication Date Title
MX2019010600A (es) Usos médicos para tratar hepatitis c.
UA116087C2 (uk) Композиція для лікування вірусу гепатиту c
AU2013318309A8 (en) Methods for treating hepatitis C
MX2016005393A (es) Metodos para tratar vhc.
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201390190A1 (ru) Ингибиторы вируса гепатита с
GB201103062D0 (en) Method
HK1209320A1 (en) Methods for treating hepatitis c
EA201270616A1 (ru) Ингибиторы вируса гепатита с
SA516370684B1 (ar) مثبطات بوليمراز فيروس الالتهاب الكبدي سي
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
MX2014013752A (es) Inhibidores de nampt.
EP2600835A4 (en) COMBINATIONS OF INHIBITORS OF HEPATITIS C VIRUS
PH12014502513A1 (en) Nampt inhibitors
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
SG195383A1 (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
PH12016502559A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
MX348311B (es) Inhibidores nampt.
ZA201404494B (en) Method for treating hepatitis c virus infection using quercetin-containing compositions
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
EP2854799A4 (en) METHOD FOR TREATING INFECTION WITH SCEDOSPORIUM SPECIES

Legal Events

Date Code Title Description
FG Grant or registration